Summary
Background: Intermediate-stage hepatocellular carcinoma (HCC), for which transarterial chemoembolization (TACE) constitutes the standard of care, is a patient subgroup with significant heterogeneity in clinical outcome. Sources of variation relate to differences in tumour burden, hepatic reserve, ethnicity and treatment modalities.
Increasing research efforts have been dedicated to minimise the clinical diversity of this patient population and enhance optimal provision of treatment.
Aim: To comprehensively review the diverse prognostic models that have been proposed to refine the prognostic prediction of patients with HCC undergoing TACE. 
| INTRODUCTION
Approximately 60% of newly diagnosed patients with hepatocellular carcinoma (HCC) are incurable. 1 Unlike other solid tumours, HCC poses a wide range of challenges stemming from the extent of spread of malignancy combined with the underlying liver dysfunction. These independent prognostic domains integrate with the patient's overall fitness, captured by the Performance Status (PS) score, to dictate the natural course of the disease. Over the past two decades, the coherent integration of individual prognostic traits into composite staging algorithms has represented a key advancement in the management of HCC.
Among the myriad of scores in HCC, the Barcelona Clinic Liver Cancer (BCLC) is a validated and widely applied staging algorithm, due to its integration of prognostication and treatment allocation. 1, 2 According to the BCLC algorithm patients with liver-restricted HCC, preserved Child-Turcotte-Pugh (CTP) class and good PS who cluster into the "intermediate" (BCLC-B) stage. While approximately 50% of intermediate-stage patients are alive 2 years after diagnosis even without treatment, 3 predicted median overall survival (OS) is highly variable, ranging between 11 and 45 months. 4, 5 It is universally recognised that such a wide variation in survival results from a significant degree of disease heterogeneity that is not adequately captured by current staging systems, where various degrees of liver dysfunction, tumour burden and other factors including age, comorbidities and aetiology of underlying chronic liver disease coexist within the unifying label of "intermediate-stage
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The issue of disease heterogeneity plays a major role in the administration of trans-arterial chemoembolization (TACE). TACE is indicated as first-line treatment in asymptomatic patients with compensated cirrhosis with a CTP score <8, PS 0 and lack of portal vein thrombosis or extra-hepatic spread. This is supported by level I evidence emerging from two randomised controlled trials showing that TACE reduces mortality by approximately 50%. 6, 7 The beneficial effect of TACE was further consolidated by two meta-analyses, 8 where its magnitude was however re-dimensioned due to patient and procedural heterogeneity. 9 Given the palliative intent of TACE, survival extension must be carefully weighed against treatment-related morbidity and mortality.
TACE may worsen the underlying liver dysfunction and, although administered safely in most instances, it carries a potential risk of post-procedural mortality reported to be as high as 10%. 10, 11 Increasing clinical evidence suggests that the survival benefit deriving from loco-regional therapies is not evenly distributed across all the patients receiving TACE. Despite meeting eligibility criteria, a subset of patients may not respond to therapy, which suggests the need for more accurate prognostication. Furthermore, patients with initial radiological response to treatment may subsequently become ineligible to repeat embolisation due to worsening liver failure, lack of adequate arterial access or disease progression. The lack of shared retreatment criteria across different institutions has made a harmonised definition of "TACE refractoriness" the subject of intense debate.
12,13
The evolving experience in the administration of TACE has progressively widened its positioning within the treatment armamentarium of HCC to include both earlier-stage patients (ie, BCLC-A) unsuitable for curative therapies as well as a wide range of cases with BCLC-C stage tumours either due segmental, non-occlusive portal vein thrombosis, extra-hepatic spread, symptomatic disease or liver dysfunction. The progressively broadening use of TACE beyond the recommended eligibility criteria has further widened the heterogeneity in treatment-induced survival benefit, making patient selection and prognostication increasing difficult tasks for clinicians.
Furthermore, the use of TACE beyond BCLC-B staging criteria relies on far less stronger evidence and such approach might potentially be futile in some patients, depriving or postponing the delivery of potentially more efficacious alternative treatments including sorafenib or radioembolisation.
14 Increasing research efforts have been dedicated to the identification of optimal stratifying characteristics in TACE candidates, with the intended benefit to identify patients whose survival gain following initial TACE is anticipated to be very small and migrate them to alternative, more efficacious treatments. 15 Some of these models are devised to provide clinicians with objective re-treatment criteria based on dynamic changes of clinical and radiological parameters following initial treatment, with the intent to spare repeat embolisation for those patients displaying deteriorating scores for whom further treatment may be more harmful. 16 There is no clear consensus regarding the true clinical utility of the growing number of proposed scores, nor documented evidence as to which one performs best. As a result, despite being the subject of an intense academic debate, none of the proposed clinical scores has exerted a real change in clinical practice.
Here, we portray the sources of heterogeneity affecting treat- of the cases. 24 While accurate selection of patients with liver dysfunction might be an option when TACE is used as a bridging therapy to transplantation, 25 the high risk of short-term morbidity and mortality generally discourages such approach in the palliative setting.
| Procedure-related factors
Since the early attempts in the therapeutic embolisation of liver tumours in the 1970s, TACE has undergone significant technical advances to improve procedural efficacy and safety. 26 Its anticancer effects rely on the trans-catheter occlusion of the tumour-feeding vessels following selective infusion of cytotoxic agents through peripheral arterial access, generally obtained by femoral puncture.
TACE is however a poorly standardised technique across institutions,
with a number of treatment-related variables described to influence outcome.
Selection of the dominant tumour-feeding artery is largely operator-dependent. A pre-procedural angiogram is necessary to guide selection of vessels that are likely to induce maximal tumour necrosis and minimal hepatotoxicity. Selective targeting of the tumour-feeding arteries is essential to achieve complete necrosis, especially in tumours >3 cm. 27 The relative effect of tumour ischaemia over the cytotoxic activity of intra-arterial chemotherapy is an unresolved question in the administration of TACE. A number of cytotoxics including anthracyclines or cisplatin are currently in use, with no clear consensus as to the most efficacious compound. 28 In a recent phase II/III trial, comparing embolisation alone vs chemoembolisation with cisplatin using a sequential treatment schedule showed higher response rates when cisplatin was added to the schedule (67 vs 47%) in the absence, however, of significant differences in survival. 18 In conventional TACE (cTACE) protocols, drugs are infused in form of an emulsified suspension in iodised oil (lipiodol) prior to administration of the embolising agent (gelfoam or polyvinyl alcohol particles) and previous studies have shown that optimal lipiodol impregnation of the target nodule preludes improved survival outcomes following TACE, making this a frequently utilised marker to identify a successful procedure in routine practice. 29 The use of drug-eluting beads TACE (DEB-TACE) has arisen as an alternative approach to cTACE. In DEB-TACE, embolisation and drug elution into the tumour happen concurrently through the use of chemotherapy-impregnated microspheres, which yield an improved intra-hepatic delivery of cytotoxics and reduced systemic diffusion. 30 The prospective randomised Precision V study, which evaluated cTACE vs DEB-TACE in 212 cirrhotic patients confirmed an improved tolerability and higher rates of complete response of DEB-TACE but failed in demonstrating a survival difference between the groups. 31 A second, smaller trial comparing DEB-TACE with bland embolisation reported a 6.2 weeks difference in time to radiological progression, with similar adverse event profile. 32 Based on improved safety and local pharmacokinetics, the use of DEB-TACE has rapidly expanded, and a recently published case series of 104 patients, 60% of which were BCLC-B and 95% within Child A functional class revealed a median OS of 48.6 months following treatment. 4 The criteria guiding the assessment of treatment response as well as the planned follow-up intervals are also highly influential in affecting the prognosis of TACE candidates. There is little evidence to inform clinicians whether TACE should be repeated periodically at fixed intervals, 33 or whether patients should be treated upon evidence of radiological progression. In the original randomised trial by Llovet, TACE was administered at study baseline, 2, 6 months, then every 6 months thereafter until "untreatable progression" defined by portal vein or systemic spread, 6 while in the study by Lo the retreatment schedule was shorter, with pre-planned sessions every 2 months until unacceptable toxicity or disease progression. 7 By no means, however, these represent standard criteria for retreatment and a large number of institutions prefer adopting an " a la d emande" approach, guided by the evidence of radiologically proven disease progression.
It is universally recognised that standard Response Evaluation
Criteria In Solid Tumours (RECIST) 34 patients satisfied B3 criteria in the study, while the other subclasses were populated by at least 100 patients each. 38 The authors therefore proposed a modification to the score by merging the B3 and B4 strata, and constructed an alternative three-tiered prognostic system patents. 41 More importantly, in the latter study, re-assessment of each individual variable revealed a lack of significance for raised bilirubin, a prognostic factor that had in fact achieved borderline significance in the original paper. 15 For all these reasons, a modi- It has however been argued that the score gives equal prognostic weighting to each parameter of the CTP class deterioration, some of which (ie, ascites, encephalopathy) are subjective, less reproducible and may have a stronger prognostic role compared to worsening liver biochemistry. 43 The latter being not solely reflection of progressive hepatic failure but also intercurrent sepsis, or-in the case of hypoalbuminaemia-malnutrition 44 and cancer-related systemic inflammation. 45 The confounding effect of infection has in fact not Despite the uncertainties around the biologic qualification of the parameters constituting the ART score and the acknowledged limitations, the potential to identify a subset of high risk patients, whose expected survival of 7 months approaches that of advanced untreated HCC, 46 is clinically appealing and potentially practicechanging feature of this model, which might favour early treatment migration of patients with poor prognostic features in an attempt to maximise survival outcomes.
Following on from the initial experience, in a separate study consisting of a pooled analysis of 109 patients derived from the same two retrospective cohorts, Hucke et al. Explored the prognostic utility of the sequential use of the ART score in patients undergoing multiple TACE sessions. 47 The re-assessment of ART in patients undergoing second (n=109), third (n=77) and fourth TACE (n=29) showed adequate prognostic sub-classification at each time point despite the decreasing number of analysed patients, allowing the investigators to conclude that worsening of the ART score to >2.5 at any stage of the sequential loco-regional retreatment of HCC is harbinger of a poorer prognosis and should preclude further TACE.
When tested in a multivariate analysis of prognostic traits prior to TACE-3, the ART score outweighed the impact of tumour burden and AFP changes throughout treatment, to suggest an improved accuracy in detecting treatment-induced survival benefit over common clinico-pathologic variables.
Expanding on these findings, which supported the role of the ART score as a prognostic trait and an objective re-treatment criterion, the same group investigated its positioning in the context of a compound algorithm named "START strategy" devised to select TACE candidates based on optimal prognostic features exhibited prior to initial TACE (STATE score) followed by sequential ART score re-assessment to establish suitability for retreatment. 40 Based on previous observations showing that hypoalbuminaemia and elevated C-reactive protein levels are prognostic in HCC, 45, 48 Hucke and colleagues derived the STATE prognostic score combining pre-TACE albumin levels with tumour burder classified by the up-toseven criteria 49 and CRP levels. According to the model, a final score This point is of major consequence given the recent publication of an Italian study showing only 51 of 344 patients (15%) to be eligible for ART score testing based on the original eligibility criteria, 42 suggesting a reduced applicability of the score that replicates the limitations noted in the Japanese study. 51 Furthermore, when each variable of the ART score was tested, CTP class deterioration emerged as the sole predictor of OS, with no prognostic role found for radiological response to initial TACE or AST increase, which might the wider differences in the time of biochemical re-assessment, often extending to 3-4 months post-initial TACE. as an unaddressed confounder in a population with higher proportion of alcoholic cirrhosis. 42 Despite the optimal features displayed by the ART strategy in the selection of TACE candidates, the lack of external validity emerged from the two studies has questioned its clinical reliability.
Interestingly, in an independent multicentre clinical study including >700 patients from Europe and Asia, the use of the ART score without strict application of a 90-day interval and including patients who achieved complete response after TACE-a setting that better reproduces routine clinical practice-has demonstrated a better clinical performance of the score, suggesting that patient selection and time of biochemical re-assessment might be strong determinants influencing its prognostic accuracy. 53 In the light of the several issues demonstrated during external validation, prospective evaluation is a mandatory step before either the START or the ART strategies can inspire treatment changes in the clinical arena.
| The ABCR score
The criticalities emerged from the independent evaluation of the ART score broadened the interest towards prognostic scores in TACE candidates, prompting other investigators to explore novel prognostic algorithms to guide the delivery of TACE. The ABCR score is based on four established prognostic parameters in HCC including AFP>200 ng/mL at baseline (+1 point), BCLC stage (+2 and +3 points for stage B and C), increase in CTP by ≥2 from baseline (+2 points), and presence of radiological response (À3 points). 54 In the derivation cohort, patients with an ABCR score ≤2 (n=105) achieved a median OS of 35 months, compared to 6 in patients scoring ≥3 (n=23). Validation was performed in an internal (n=78) and an external cohort | 1519
| Inflammation-based prognostic models
The presence of a cancer-related pro-inflammatory diathesis is a pathogenic and prognostic hallmark of malignancy. 55 Systemic inflammation has been recognised as a stage-independent prognostic factor in most tumours, [56] [57] [58] including HCC. 44, 59 Widely available, objective laboratory parameters including CRP, albumin or reactive changes in full blood count parameters including the neutrophil or platelets-to-lymphocytes ratios (NLR, PLR) are validated inflammation-based markers in HCC. 45 The interplay between inflammation and the prognosis of intermediate-stage HCC patients is complex and results from the dynamic changes in inflammatory mediators secondary to the presence of tumour-host interactions as well as treatment. These must also occur despite a prior change in the choice of chemotherapeutic agent or re-analysis of the feeding artery to ensure TACE therapy has been optimised. 12, 70, 71 Globally, there is debate regarding the chosen cut-off of two ineffective TACE treatments to define TACE failure/refractoriness. Furthermore, in some countries, the definition of ineffective TACE is considered to be progressive disease after the first and second TACE procedures, without considering the other aspects proposed by the Japanese guidelines. Therefore, the JSH definition was subsequently validated in a small retrospective study of 45 patients receiving sorafenib therapy, who had experienced TACE failure. In this study, the number of ineffectual TACE treatments received was the only significant independent variable associated with survival on multivariate analysis.
Those who received up to two ineffectual TACE treatments prior to sorafenib therapy had longer overall survival compared with those who had received ≥3 ineffective TACE prior to sorafenib (OR: 4.40, 95% CI: 1.11-17.37; P<.035).
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This supports a survival benefit of swapping to other treatments once TACE proves ineffectual, rather than subjecting patients to multiple TACE treatments in the absence of survival benefit. OS was significantly shorter in those who received ≥2 ineffectual TACE treatments (8 months, 95% CI: 5.7-10.4 months), however, in this study the median survival time for those receiving ≤2 treatments was not calculated. Furthermore, this was a small retrospective study, and further prospective studies in mixed-ethnicity cohorts are warranted to definitively determine futility rules in HCC management. All authors approved the final version of the manuscript.
| CONCLUSIONS

